2020
Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors
Trendowski MR, Wheeler HE, El-Charif O, Feldman DR, Hamilton RJ, Vaughn DJ, Fung C, Kollmannsberger C, Einhorn LH, Travis LB, Dolan ME. Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors. Clinical Cancer Research 2020, 26: 6550-6558. PMID: 32998964, PMCID: PMC7744329, DOI: 10.1158/1078-0432.ccr-20-2682.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBleomycinCancer SurvivorsCisplatinEtoposideFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticGenome-Wide Association StudyHumansIfosfamideMaleMiddle AgedNeoplasmsNeurotoxicity SyndromesPolymorphism, Single NucleotidePrognosisRisk FactorsSurvival RateVinblastineConceptsCumulative cisplatin doseCisplatin doseSevere neurotoxicityCancer survivorsRisk factorsAdult-onset cancer survivorsLifestyle/behavioral factorsCisplatin-induced neurotoxicityDizziness/vertigoNeuro-otological symptomsPeripheral sensory neuropathyPoor overall healthPeripheral motor neuropathyImportant risk factorTesticular cancer survivorsQuality of lifeSerum platinum levelsDose adjustmentMotor neuropathyRaynaud's phenomenonSensory neuropathyNeurotoxicity riskPsychotropic medicationsClinical examinationMedical history
2019
Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy
Trendowski MR, El-Charif O, Ratain MJ, Monahan P, Mu Z, Wheeler HE, Dinh PC, Feldman DR, Ardeshir-Rouhani-Fard S, Hamilton RJ, Vaughn DJ, Fung C, Kollmannsberger C, Mushiroda T, Kubo M, Hannigan R, Strathmann F, Einhorn LH, Fossa SD, Travis LB, Dolan ME. Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy. Clinical Cancer Research 2019, 25: 5913-5924. PMID: 31296530, PMCID: PMC6774840, DOI: 10.1158/1078-0432.ccr-19-0113.Peer-Reviewed Original ResearchAdverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors.
Abu Zaid M, Dinh PC, Monahan PO, Fung C, El-Charif O, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Cook R, Althouse S, Ardeshir-Rouhani-Fard S, Sesso HD, Huddart R, Mushiroda T, Kubo M, Dolan ME, Einhorn LH, Fossa SD, Travis LB, _ _. Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors. Journal Of The National Comprehensive Cancer Network 2019, 17: 459-468. PMID: 31085753, PMCID: PMC6712564, DOI: 10.6004/jnccn.2018.7109.Peer-Reviewed Original ResearchConceptsTesticular cancer survivorsPlatinum-based chemotherapyRisk factorsErectile dysfunctionCancer survivorsFirst-line platinum-based chemotherapyHealth outcomesMultivariable binary logistic regression analysisCisplatin-based chemotherapy regimenCardiovascular disease risk factorsVigorous-intensity physical activityPrevalence of hypogonadismTestosterone replacement therapyDisease risk factorsSerum testosterone levelsBody mass indexBinary logistic regression analysisYounger median ageAdverse health outcomesLogistic regression analysisYears of ageAnxiety/depressionGenetic risk factorsChemotherapy regimenSymptomatic patients